Search Results - Gyaw, Shwe

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose

    Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose by Krieter, Philip, Gyaw, Shwe, Crystal, Roger, Skolnick, Phil

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose

    Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose by Krieter, Philip, Chiang, Nora, Gyaw, Shwe, Skolnick, Phil, Crystal, Roger, Keegan, Fintan, Aker, Julie, Beck, Melissa, Harris, Jennifer

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose

    Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose by Krieter, Philip, Gyaw, Shwe, Chiang, C. Nora, Crystal, Roger, Skolnick, Phil

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder

    Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder by McCann, David J., Chen, Hegang H., Devine, Eric G., Gyaw, Shwe, Ramey, Tatiana

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  5. 5
    Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects

    Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects by Krieter, Philip, Chiang, C Nora, Gyaw, Shwe, Skolnick, Phil, Snyder, Rebekah

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices vs. a Common Improvised Nasal Naloxone Device

    Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices vs. a Common Improvised Nasal Naloxone Device by Krieter, Philip A., Chiang, C. Nora, Gyaw, Shwe, McCann, David

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA‐Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device

    Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA‐Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device by Krieter, Philip A., Chiang, C. Nora, Gyaw, Shwe, McCann, David J.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence

    Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence by Gilgun-Sherki, Yossi, Eliaz, Rom E, McCann, David J, Loupe, Pippa S, Eyal, Eli, Blatt, Kathleen, Cohen-Barak, Orit, Hallak, Hussein, Chiang, Nora, Gyaw, Shwe

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    Sym001, the First Recombinant Polyclonal Rhesus-D Specific Antibody Product, Was Safe and Well-Tolerated in a Placebo-Controlled Randomized Phase I Trial

    Sym001, the First Recombinant Polyclonal Rhesus-D Specific Antibody Product, Was Safe and Well-Tolerated in a Placebo-Controlled Randomized Phase I Trial by Hjelmström, Peter, Hallén, Bengt, Lindenstroem, Ewa, Gyaw, Shwe

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: